Roche signs major partnership with China's Hansoh to co-develop antibody-drug conjugates
read at STAT ↗DealPositive
Roche announced a deal with China's Hansoh Pharmaceutical Group to develop a portfolio of antibody-drug conjugates (ADCs).
The agreement is described as massive, indicating a significant collaboration aimed at leveraging Hansoh's presence in China and Roche's ADC expertise.
The partnership reflects Roche's ongoing strategy to expand its drug development pipeline in China, aligning with broader industry trends of seeking growth in the Chinese market.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Roche continues to look to China for new drugs”
read at STAT ↗527 words · retrieved 23m ago
comments(0)
5-min edit window · permanent after that